Sun Pharma successfully acquires InSite Vision

03 Nov 2015 Evaluate

Sun Pharmaceutical Industries (Sun Pharma) has successfully completed acquistion of InSite Vision Incorporated (InSite). The acquisition was completed by means of a short-form merger under Delaware law. Post the short-form merger, InSite has become an indirect wholly owned subsidiary of Sun Pharma.

As a result of the merger, each issued and outstanding share of InSite common stock (other than shares of InSite common stock owned by the indirect wholly owned subsidiaries of Sun Pharma or InSite (or held in its treasury), any subsidiary of the indirect wholly owned subsidiaries of Sun Pharma or InSite, or by any stockholder of InSite who or which is entitled to and properly demands and perfects appraisal of such shares of InSite common stock pursuant to, and complies in all respects with, the applicable provisions of Delaware law) was converted into the right to receive US$0.35 and each option to acquire shares of InSite common stock that is unexercised and outstanding as of immediately prior to the merger, to the extent not then vested or exercisable, became fully vested and exercisable and was converted into the right to receive a cash payment in an amount equal to the excess, if any, of $0.35 over the exercise price of such option to acquire shares of InSite common stock. 

Sun Pharma is the fifth largest specialty generic pharmaceutical company in the world. The company provides high quality, affordable medicines trusted by healthcare professionals and patients in over 150 countries worldwide.

Sun Pharma Inds. Share Price

1795.30 -9.65 (-0.53%)
08-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1795.30
Dr. Reddys Lab 1267.15
Cipla 1497.45
Zydus Lifesciences 924.35
Lupin 2071.35
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×